SSShiqun Sun

Shiqun Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shiqun Sun has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study

    by Xian Cui, Chunbei Yi, Hui Zhang, Yaqian Xu, Chongyu Ding, Zhaojun Wang, Shiqun Sun, Xiangwei Li

    Background: While DNA methylation ( DNAm )‐based algorithms of aging show promise for predicting age‐related diseases, their comparative utility for incident cardiovascular disease ( CVD ) remains underexplored. We aimed to systematically compare 13 DNAm algorithms in relation to CVD risk in older adults. Methods: This prospective cohort study included 2112 participants from the US HRS (Health and Retirement Study) with baseline DNAm data (2016) and 6‐year follow‐up. DNAm profiling was performed using the Infinium MethylationEPIC BeadChip kit ( EPIC , Illumina, San Diego, CA ). Thirteen widely used DNAm algorithms of aging were evaluated. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs per 1‐SD increase in risk scores for incident CVD, including any CVD, congestive heart failure, and stroke. Results: During a median of 37 months’ follow‐up, a total of 288 CVD cases (congestive heart failure, 38; stroke, 152) were observed. Zhang_DNAmAge, methylation Pace of Aging, and DNAmGrimAgeAcc showed positive associations with any CVD risk, with HRs per SD increase of 1.25 (95% CI, 1.07–1.45), 1.16 (95% CI, 1.02–1.33), and 1.24 (95% CI, 1.05–1.47), respectively. For specific CVD subtypes, DNAmGrimAge was associated with congestive heart failure risk ( HR , 1.47 [95% CI, 1.11–1.95]), while both mPoA ( HR , 1.24 [95% CI, 1.03–1.49]) and HorvathAcc ( HR , 1.28 [95% CI , 1.07–1.55]) predicted incident stroke. Significant dose–response relationships ( P ‐trend <0.05) were observed for Zhang_DNAmAge and DNAmGrimAgeAcc across all CVD outcomes. Conclusions: Zhang_DNAmAge, methylation Pace of Aging, and DNAmGrimAgeAcc function as independent predictors of incident CVD . These epigenetic biomarkers may improve early CVD detection and risk stratification in aging populations.


  • Open Access

    Associations of DNA Methylation Algorithms of Aging With Cardiovascular Disease and Mortality Risk Among US Older Adults

    by Xian Cui, Shiqun Sun, Hui Zhang, Yulu Gong, Darong Hao, Yaqian Xu, Chongyu Ding, Jing Wang, Tongyan An, Jinlong Liu, et al.

    Background: Several DNA methylation (DNAm) algorithms have recently emerged as robust predictors of aging and adverse health outcomes in older adults, offering valuable insights into cardiovascular disease (CVD) risk stratification. However, their predictive performance for CVD varies significantly. This study aimed to systematically investigate the associations of 12 widely used DNAm algorithms with CVD and mortality risk. Methods: Data from the NHANES (National Health and Nutrition Examination Survey) 1999 to 2002 were used to assess 12 DNAm algorithms (eg, HannumAgeacc, PhenoAgeacc, GrimAgeMortacc, GrimAge2Mortacc) in relation to CVD risk and mortality. Two cohorts were analyzed: one for CVD risk (n=1230) and another for CVD mortality risk (n=1606). DNAm was measured using the Infinium Methylation EPIC BeadChip kit (Illumina). Odds ratios (ORs) and hazard ratios (HRs), along with 95% CIs per SD increase of these DNAm algorithms, were calculated. Results: Significant associations were observed for GrimAgeMortacc and GrimAge2Mortacc with coronary heart disease and heart attack, with multivariable‐adjusted ORs per SD increase ranging from 2.15 to 2.76. However, several algorithms exhibited no significant association with self‐reported prevalent CVD. For mortality risk, HannumAgeacc, PhenoAgeacc, ZhangAgeacc, GrimAgeMortacc, and GrimAge2Mortacc were significantly associated with CVD mortality. The multivariable‐adjusted HRs per SD increase were 1.19 (95% CIs, 1.05–1.34), 1.13 (95% CIs, 1.01–1.26), 1.63 (95% CI, 1.08–2.47), 1.90 (95% CIs, 1.51–2.40), and 1.87 (95% CIs, 1.51–2.32), respectively. These associations were consistent across biological sex, age (≥50 and <65 versus ≥65 years), and race and ethnicity groups. Conclusions: DNAm algorithms, particularly GrimAgeMortacc and GrimAge2Mortacc, may serve as valuable tools for CVD risk stratification and mortality risk assessment.


  • Open Access

    Comparison of Effects of Different Statins on Contrast‐Induced Acute Kidney Injury in Rats: Histopathological and Biochemical Findings

    by Xiao-Lei Wang, Tuo Zhang, Liu-Hua Hu, Shi-Qun Sun, Wei-Feng Zhang, Zhe Sun, Ling-Hong Shen, Ben He

    Statins are a promising new strategy to prevent contrast‐induced acute kidney injury (CI‐AKI). In this study we compared the ameliorative effect of different statins in a rat model of CI‐AKI. Sprague‐Dawley rats were divided into five groups: control group; CI‐AKI group; CI‐AKI + rosuvastatin group (10 mg/kg/day); CI‐AKI + simvastatin group (80 mg/kg/day); and CI‐AKI + atorvastatin group (20 mg/kg/day). CI‐AKI was induced by dehydration for 72 hours, followed by furosemide intramuscular injection 20 minutes before low‐osmolar contrast media (CM) intravenous injection. Statins were administered by oral gavage once daily for 3 consecutive days before CM injection and once 4 hours after CM injection. Rats were sacrificed 24 hours after CM injection, and renal function, kidney histopathology, nitric oxide (NO) metabolites, and markers of oxidative stress, inflammation, and apoptosis were evaluated. The results showed that atorvastatin and rosuvastatin but not simvastatin ameliorated CM‐induced serum creatinine elevation and histopathological alterations. Atorvastatin and rosuvastatin showed similar effectiveness against CM‐induced oxidative stress, but simvastatin was less effective. Atorvastatin was most effective against NO system dysfunction and cell apoptosis, whereas rosuvastatin was most effective against inflammation. Our findings indicate that statins exhibit differential effects in preventing CI‐AKI when given at equivalent lipid‐lowering doses.